GlassScriptPhysician profile
Patricia E Scallan
NPI 1568451862
$3,832.17
in general payments reported to CMS, 2019-2025
25 companies · $760 in 2025
The $760 reported for 2025 was more than what 83% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
See the full distribution for Plastic Surgery within the Head & Neck
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $315 · 2021: $820 · 2022: $534 · 2023: $612 · 2024: $490 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $803.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $763.76 | 2019-2025 | |
| Genzyme Corporation | $475.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $406.03 | 2019-2025 | Dupixent |
| Acclarent, INC | $229.13 | 2021-2024 | Acclarent Aera |
| Medtronic, INC. | $165.89 | 2023 | Propel |
| Novartis Pharmaceuticals Corporation | $127.69 | 2019-2025 | |
| Abbvie INC. | $125.21 | 2021-2025 | Qulipta |
| Inspire Medical Systems, INC. | $122.13 | 2025 | Inspire |
| Neurent Medical Limited | $120.39 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Arbor Pharmaceuticals, INC. | $70.77 | 2019 | |
| Kaleo, INC. | $66.76 | 2019-2024 | Auvi-Q |
| Intersect Ent, INC. | $54.49 | 2019-2020 | |
| Smith+Nephew, INC. | $44.52 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $33.21 | 2023 | Ryaltris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $30.81 | 2019 | |
| Pfizer INC. | $30.69 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $28.98 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $27.59 | 2025 | Neffy |
| Stryker Corporation | $21.97 | 2021 | |
| Phadia US INC. | $21.13 | 2024 | Immunocap |
| Amgen INC. | $20.44 | 2025 | Tezspire |
| Allergan, INC. | $14.88 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.45 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Scallan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.